Different tracers have been proposed in nuclear medicine to visualize neuroendocrine tumours; the majority are based on specific uptake mechanisms while some are aspecific. Among the most important gamma-emitting tracers, radiolabelled metaiodobenzylguanidine (123I or 131I-MIBG) and 111In-pentetreotide should be mentioned. In particular, good results can be obtained with 111In-pentetreotide scanning, which visualizes more than 70% of all neuroendocrine tumours and in some indications, as in gastro-entero-pancreatic (GEP) tumours, has a diagnostic sensitivity superior to that of conventional radiological imaging. Radiolabelled monoclonal antibodies have at present only a storical value, while a series of new peptides represent interesting subjects in areas currently being regarded. Positron emission tomography (PET) is a successful modality to detect cancer and recent years, has demonstrated a great diagnostic value in a large series of tumour types. 18F-deoxyglucose (FDG)-PET has also been used to diagnose tumours of neuroendocrine origin. Even if 18F-FDG has been successfully and widely employed in oncology, it has not demostrated a significant uptake in well differentiated neuroendocrine tissues. On the contrary, other positron emitter tracers seem to be more promising. A serotonin precursor 5-hydroxytryptophan (5-HTP) labelled with 11C has shown an increased uptake in carcinoids. This uptake seems to be selective and some clinical evidence has demonstrated that it allows the detection of more lesions with PET than with CT or octreotide scintigraphy. Another radiopharmaceutical in development for PET is 11C L-DOPA, which seems to be useful in visualizing endocrine pancreatic tumours. This Review summarizes the potential of several nuclear medicine techniques in the diagnosis of neuroendocrine tumours and stresses the renewed role of nuclear medicine in the management of this disease.
We recently demonstrated in a clinical trial the ability of a new protocol, IQ SPECT, to acquire myocardial perfusion imaging (MPI) studies in a quarter of the time (12 s/view) of the standard protocol, with preserved diagnostic accuracy. We now aim to establish the lower limit of radioactivity that can be administered to patients and the minimum acquisition time in SPECT MPI using an IQ SPECT protocol, while preserving diagnostic accuracy. Methods: An anthropomorphic cardiac phantom was used to acquire clinical rest scans with a simulated in vivo distribution of 99mTc-tetrofosmin at full dose (740 MBq) and at doses equal to 50%, 25%, and 18%. For each dose, 2 sets of images were acquired, with and without a transmural defect (TD). Variable acquisition times were also used for each dose. We analyzed raw data and reconstructed images, including no correction and correction for attenuation (AC), for scatter (SC), or for both (ACSC). Images were evaluated qualitatively and quantitatively in order to assess left ventricle (LV) wall thickness (full width at half maximum of the medial sections), TD, and cavity contrast in the LV wall. Data were compared across different acquisition times within the same dose and across doses with the same acquisition time. Results: Images were visually scored as very-good quality except those acquired with 4 s/view or less at 100% dose and 6 s/view or less with 50%, 25%, or 18% dose, due to false-positive defects. LV wall thickness was not significantly different among all acquisitions. Cavity contrast remained unchanged within the same dose for all images and tended to be higher in AC and ACSC images. TD contrast remained unchanged within the same dose for all images. In SC and no-correction images, contrast was constant for all doses. AC images had significantly higher TD contrast values, and ACSC images showed a drop in TD contrast for a 50% dose. Conclusion: IQ SPECT effectively preserved both image quality and quantitative measurements with reduced acquisition time or administered dose in a phantom study. These findings suggest that approximately one eighth of the time, compared with standard protocols with a full dose, or a lower dose at an acquisition time of 12 s/view can be applied in MPI without the loss of diagnostic accuracy.
The aim was to evaluate the incremental diagnostic rate of F-18 fluoro-fluorodeoxygulose positron emission tomography/computed tomography (F-18 FDG-PET/CT) in patients with negative I-131 whole body scans and high Tg levels. The secondary end points were correlations between F-18 FDG-PET/CT positive results and Tg levels and comparison between F-18 FDG-PET/CT accuracy in patients “on-therapy” with suppressed thyroid stimulating hormone (TSH) and those with high TSH levels. We studied 52 patients who had undergone total thyroidectomy and remnant ablation; they had high Tg levels (average = 156 ng/mL; SD ± 274) after 3 weeks of levothyroxine withdrawal and negative I-131 total body scans after therapeutic doses. We noted a statistically significant positive correlation between F-18 FDG-PET/CT positive results and Tg levels, irrespective of levothyroxine therapy regimen. Tg levels between F-18 FDG-PET/CT positive/negative groups were significantly different and we did not note any statistically significant correlation between F-18 FDG-PET/CT results and TSH levels, tumor size, and combination of Tg/TSH levels. Our results indicate that F-18 FDG-PET/CT is a useful diagnostic tool in patients with differentiated thyroid carcinoma and with negative I-131 total body scans and high Tg levels. The levothyroxine therapy regimen does not influence F-18 FDG-PET/CT results and the rate of F-18 FDG-PET/CT positive results appears to correlate with the Tg levels. The highest accuracy is reached when the study is performed for patients with Tg levels higher than 21 ng/mL.
Prostate cancer represents one of the most important health problems in industrialized countries. It is the second leading cause of cancer-related death in the United States. Therapeutic options are different according to the stage of the disease at the diagnosis. Patients with localized disease may be treated with surgery or radiation, whereas the treatment for patients with a metastatic disease is purely palliative. Hormonal treatment represents the standard therapy for stage IV prostate cancer, but patients ultimately become unresponsive to androgen ablation and are classified as hormone-refractory prostate cancer patients. The molecular mechanisms involved in progression in hormone resistance are characterized by mutations, down and up-regulation in the androgen receptor gene, mutations in p53 and over-expression of Bcl2 and other alterations in genes and in gene expression. The important thing is that we understand these mechanisms to define potential therapeutic agents for the treatment of hormone-refractory prostate cancer patients. Conventional options for patients with hormone-refractory prostate cancer include secondary hormone therapy, radiotherapy and cytotoxic chemotherapy. The commonest antineoplastic agents are mitoxantrone, estramustine and taxanes. Despite an improvement In the palliative benefit, none of these agents has demonstrated a beneficial impact on the overall survival of patients. Therefore, there is no standard therapy for these patients, thus we need new approaches which should be studied in clinical trials. The evaluation and incorporation of new agents into current treatment regimens could have a role in the treatment of hormone-refractory prostate cancer, but their efficacy has not yet been demonstrated.